Cargando…

Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant

Targeted therapies have improved the outcome of cancer, but their efficacy is intrinsically limited by the emergence of subclones with a mutation in the gene encoding the target protein. A few examples of collateral sensitivity have demonstrated that the conformational changes induced by these mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Libre, Camille, Moro-Sibilot, Ludovic, Giraud, Stéphane, Martin, Laetitia, Verhoeyen, Els, Costa, Caroline, Chebel, Amel, Bissay, Nathalie, Salles, Gilles, Genestier, Laurent, Sujobert, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226254/ https://www.ncbi.nlm.nih.gov/pubmed/32272741 http://dx.doi.org/10.3390/cancers12040901

Ejemplares similares

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
por: Hamasy, A, et al.
Publicado: (2017)

Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models
por: Lim, Ye Seul, et al.
Publicado: (2022)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Correction to Lancet Oncol 2013; 14: 481
Publicado: (2013)

SAT-481 TSH Adenoma: An Elusive Diagnosis
por: Chaudhary, Hira, et al.
Publicado: (2019)

Correction to Lancet Neurol 2020; 19: 481–82
Publicado: (2020)

MON-481 Remarkable Euthyroid Hyperthyroxinemia Mistaken for Thyrotoxicosis
por: Baghel, Annavi, et al.
Publicado: (2020)

Lacticin 481 Synthetase as a General Serine/Threonine Kinase
por: You, Young Ok, et al.
Publicado: (2009)

481 Differences in Humoral and Cellular Immunity in Young and Old Individuals
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
por: Paulus, A, et al.
Publicado: (2017)

Chemical Synthesis of the Lantibiotic Lacticin 481 Reveals the Importance of Lanthionine Stereochemistry
por: Knerr, Patrick J., et al.
Publicado: (2013)

Draft Genome Sequence of Zymomonas mobilis ZM481 (ATCC 31823)
por: Zhao, Ning, et al.
Publicado: (2016)

SUN-481 Awakening Cortisol Response in Males and Females across Puberty
por: Martinez, Pedro, et al.
Publicado: (2019)

SAT-481 Pembrolizumab-Induced Thyroiditis with Negative Thyroid Peroxidase Antibody
por: Ragunanthan, Branavan, et al.
Publicado: (2020)

481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome
por: Tobacyk, Julia, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

P1243: FUNCTIONAL PRECISION ONCOLOGY FOR FOLLICULAR LYMPHOMA WITH PATIENT-DERIVED XENOGRAFT IN AVIAN EMBRYOS.
por: Zala, Manon, et al.
Publicado: (2023)

A comment to the paper by Waltman et al., Scientometrics, 87, 467–481, 2011
por: Opthof, Tobias, et al.
Publicado: (2011)

Lanyamycin, a macrolide antibiotic from Sorangium cellulosum, strain Soce 481 (Myxobacteria)
por: Mulwa, Lucky S, et al.
Publicado: (2018)

Universal ocular screening of 481 infants using wide-field digital imaging system
por: Ma, Yan, et al.
Publicado: (2018)

IS481EU Shows a New Connection between Eukaryotic and Prokaryotic DNA Transposons
por: Kojima, Kenji K., et al.
Publicado: (2023)

SAT481 Metastatic Choriocarcinoma, A Rare Cause of hCG-Mediated Hyperthyroidism
por: Jain, Shailee, et al.
Publicado: (2023)

Genetic variation among 481 diverse soybean accessions, inferred from genomic re-sequencing
por: Valliyodan, Babu, et al.
Publicado: (2021)

Melanocytic lesions ≤ 6mm: Prospective series of 481 melanocytic trunk and limb lesions in Brazil
por: Campos-do-Carmo, Gabriella, et al.
Publicado: (2021)

P481 Antifungal vaccines: An alternative approach to combat multidrug resistance in the post-antibiotic era
por: Ahmad, Aijaz
Publicado: (2022)

THU481 Glucocorticoid Regeneration By Tumor Cells Promotes Growth By Enhancing Regulatory T Cell Immunosuppression
por: Taves, Matthew D, et al.
Publicado: (2023)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Ibo van de Poel and David E. Goldberg (eds): Philosophy and Engineering. An Emerging Agenda: Springer, The Netherlands, 2009, ISBN 978-90-481-2803-7/e-ISBN 978-90-481-2804-4
por: Oosterlaken, Ilse
Publicado: (2010)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a92ov90euk29gu4mdgkvd3krn0